Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-110362
Filing Date
2025-11-12
Accepted
2025-11-12 16:11:24
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2530900d1_defa14a.htm DEFA14A 13205
2 GRAPHIC tm2530900d1_defa14aimg01.jpg GRAPHIC 126446
3 GRAPHIC tm2530900d1_defa14aimg02.jpg GRAPHIC 96746
  Complete submission text file 0001104659-25-110362.txt   314455
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-12584 | Film No.: 251472819
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)